MedTrace Logo

The Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experienced Patients

NCT03789968 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 411

Last updated 2020-10-08

No results posted yet for this study

Summary

This study will assess changes in the incidence and severity of drug interactions before and after switching antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide-based regimens in treatment experienced patients living with HIV infection.

Conditions

Interventions

DRUG

bictegravir/emtricitabine/tenofovir alafenamide

Treatment experienced patients with HIV infection that switched to a bictegravir/emtricitabine/tenofovir alafenamide-based ART regimen

Sponsors & Collaborators

  • University of Maryland, College Park

    collaborator OTHER

  • Indiana University Health

    collaborator OTHER

  • The Brooklyn Hospital Center

    collaborator OTHER

  • University of Illinois at Chicago

    collaborator OTHER

  • Nova Southeastern University

    collaborator OTHER

  • University of California, San Francisco

    collaborator OTHER

  • Thomas Jefferson University

    lead OTHER

Principal Investigators

  • Jason J Schafer, PharmD, MPH · Thomas Jefferson University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2020-09-05
Completion
2020-10-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03789968 on ClinicalTrials.gov